Join Drs Harlan Krumholz, Roger Blumenthal, Robert Harrington, Mariell Jessup, Paul Ridker, Sidney Smith, Gregg Stone, William Weintraub, and Clyde Yancy as they dissect the results of the JUPITER trial and debate the far-reaching clinical implications of this landmark study in Part 1 of the program.
In Part 2 of the program, the panelists look at the positive sides of HF-Action and TIMACS and deliberate the real lessons learned from these negative trials.
Dr Melissa Walton-Shirley asks Drs Franz Messerli and Raymond Gibbons for their thoughts on dual RAAS inhibition and on what the future holds for ACE inhibitors and angiotensin-receptor blockers following ONTARGET and TRANSCEND.
Join Drs Raymond Gibbons, Antonio Colombo, William Boden, Ph Gabriel Steg, and Valentin Fuster for another look at the COURAGE trial, as they discuss the latest data and talk about where things stand now on the larger controversy.
Dr Melissa Walton-Shirley talks to Drs Ph Gabriel Steg and Raymond Gibbons about the differences in STEMI care on both sides of the Atlantic and what US cardiologists can learn from their colleagues in Europe.
Join Drs Marc Pfeffer, PhilipPoole-Wilson, and Franz Messerli, as they talk about the use of ARBs in patients intolerant of ACE inhibitors, following the unexpected results of the TRANSCEND study, in a spirited debate moderated by heartwire journalist Lisa Nainggolan.
Drs Antonio Colombo and Renu Virmani talk about the one-year results of the SYNTAX trial, the importance of understanding registries, and the complex issue of clopidogrel duration with drug-eluting stents in a discussion moderated by heartwire journalist Shelley Wood.
Dr Philip Poole-Wilson talks to Drs Marc Pfeffer and Franz Messerli about the clinical implications of the GISSI-HF trial and how it may alter our view of the pathophysiology of heart failure.
Join Drs Valentin Fuster, William Boden, Antonio Colombo, Raymond Gibbons, Franz Messerli, Marc Pfeffer, Philip Poole-Wilson, Ph Gabriel Steg, Renu Virmani, and Harvey White as they plumb the depths of the SYNTAX (Part 1) and CARDIA trials and weigh in on the cancer scare in the SEAS study (Part 2).
Join Drs Harlan Krumholz, Robert Harrington, Steven Nissen, and Frans Van De Werf as they give clinical trials a spirited going-over, from how they are being conducted to who is conducting them, and get into some of the sticky issues around sponsorship and data management.
Join Dr Melissa Walton-Shirley as she talks to Drs Ileana Piņa, Clyde Yancy, and cardiology fellow Eiran Gorodeski about the current state of treatment for decompensated congestive heart failure, why we need to remember the fundamentals, and some exciting data from the PROTECT-1 pilot study.
Join Drs Clyde Yancy and Robert Harrington as they discuss the clinical implications of ONTARGET and ACCOMPLISH, why they are reconsidering their skepticism about combination therapies in the treatment of hypertension, and how lowering blood pressure may be more than just a numbers game.
Drs Frans Van de Werf and Gilles Montalescot talk about the results of TRANSFER-AMI, current practice for the treatment of STEMI patients, and ongoing and future trials that they hope will further clarify questions on transfer times for PCI and optimal antithrombin therapies.
Join heartwire's Larry Husten as he talks to Dr Harlan Krumholz and USA Today journalist Steve Sternberg about the decision to present the results of the ENHANCE trial at a unique opening session of the ACC 2008 Scientific Sessions, and about the response of the cardiology community and the media to the continuing controversy.
Dr Gregg Stone talks to Drs Keith Fox and Gilles Montalescot about the implications of the DES meta-analysis and the interventional cardiology late-breaking trials presented at the joint SCAI-ACC i2 2008 Scientific Sessions.
Dr Keith Fox talks to Drs Gregg Stone and Robert Harrington about why it takes so long for new evidence-based therapies to be adopted in clinical practice, the importance of national registries, and what can be done to make treatment guidelines more useful.
In conversation with heartwire news and features editor Larry Husten, Terry Ferguson MD muses on changes to daily life, decision making processes and patient care from a different perspective resulting from his new position in industry.
Join Drs Valentin Fuster, Robert Harrington, Steven Nissen, Gregg Stone, Clyde Yancy, Gilles Montalescot, Keith Fox, Frans Van de Werf, and Harlan Krumholz for an upfront and spirited discussion as they thrash out the controversies surrounding ENHANCE and STRADIVARIUS, consider the results of ONTARGET and PERISCOPE, and question the utility of surrogate end points.
Clinical trials are under attack and in the headlines. What are the proper roles of industry and academics? Who owns the data? Join two of the worlds foremost experts on clinical trials in a lively discussion of the many controversial and thorny issues surrounding ENHANCE and ACCORD.
Drs Keith Fox and Gregg Stone go into the details of this practice-changing trial as they address concerns about acute stent thrombosis and talk about ways to improve outcomes, in a discussion moderated by Dr James Ferguson.
Debate continues over drug-eluting stentsDrs Gregg Stone and Renu Virmani share their hopes and concerns for PCI and drug-eluting stents as they weigh in on the COURAGE nuclear substudy and the latest registry data on DES vs BMS in a discussion moderated by heartwire journalist Shelley Wood.
Join Dr Melissa Walton-Shirley as she talks to Drs Clyde Yancy and Roger Blumenthal about CORONA, RETHINQ, MASTER-1, and the AF/CHF trial and why sticking with the basics might be the best approach for congestive heart failure.
All about Eve: Treating women with ACSAre women really different from men? Dr Melissa Walton-Shirley questions Drs William Boden and Judith Hochman on gender differences in the treatment of acute coronary syndrome.
POISE raises questions on perioperative use of beta blockers Dr Roger Blumenthal talks with Drs Judith Hochman and Franz Messerli about the unexpected results of the POISE trial.
Drs Eric Topol and Rob Califf bring their freewheeling debate to the screen in this first-ever video Thumbs up, thumbs down, recorded at the AHA meeting in Orlando.